Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.

Saved in:
Bibliographic Details
Title: Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.
Authors: Vigneswaran, Hari T.1,2 (AUTHOR) hari.vigneswaran@ki.se, Palsdottir, Thorgerdur1 (AUTHOR), Micoli, Chiara1 (AUTHOR), Tilki, Derya3,4,5 (AUTHOR), Lin, Daniel6 (AUTHOR), Cooperberg, Matthew7 (AUTHOR), Eggener, Scott8 (AUTHOR), Falagario, Ugo Giovanni2 (AUTHOR), Möller, Axel2 (AUTHOR), Aly, Markus2 (AUTHOR), Akre, Olof2 (AUTHOR), Wiklund, Peter2 (AUTHOR), Egevad, Lars9 (AUTHOR), Grönberg, Henrik1 (AUTHOR), Nordström, Tobias1,10 (AUTHOR), Eklund, Martin1 (AUTHOR)
Source: European Urology. Jan2026, Vol. 89 Issue 1, p82-90. 9p.
Database: Academic Search Ultimate
Description
ISSN:03022838
DOI:10.1016/j.eururo.2025.10.001